Allscripts (MDRX) PT Lowered to $13 at Evercore ISI

Allscripts (MDRX) PT Lowered to $14.50 at RBC Capital

RBC Capital lowered its price target on Allscripts (NASDAQ: MDRX) to $14.50 (from $17.00) while maintaining a Outperform rating.

SunTrust Robinson Humphrey Upgrades Allscripts (MDRX) to Buy

SunTrust Robinson Humphrey upgraded Allscripts (NASDAQ: MDRX) from Hold to Buy with a price target of $16.00.

For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.

Shares of Allscripts closed at $11.52 yesterday.

Allscripts (MDRX) to Buy HealthGrid

Allscripts (NASDAQ: MDRX), a global leader in healthcare technology, today announced that it signed a definitive agreement to acquire HealthGrid Holding Company, a mobile enterprise patient engagement platform business. The agreement represents a significant expansion of the Allscripts FollowMyHealth® platform portfolio, the companys patient engagement solution focused on connecting patients with providers. Allscripts expects to close the acquisition in the second quarter of calendar 2018, subject to the satisfaction of customary closing conditions, including the expiration or termination of the waiting period under U.S. antitrust laws.

HealthGrid is a leading mobile, enterprise... More

Allscripts (MDRX) Misses Q1 EPS by 1c, Affirms Outlook

Allscripts (NASDAQ: MDRX) reported Q1 EPS of $0.16, $0.01 worse than the analyst estimate of $0.17. Revenue for the quarter came in at $518.6 million versus the consensus estimate of $530.48 million.

Allscripts affirms the following financial outlook for 2018

For earnings history and earnings-related data on Allscripts (MDRX) click here.